肖伟：深化改革 强化监管 切实保障药品高水平安全

Core Viewpoint - The newly released "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" aims to strengthen drug regulation in response to the rapid development of the pharmaceutical industry, ensuring high-quality health needs while enhancing regulatory requirements [1][8]. Group 1: Reform and Optimization of Drug Regulation - The regulations provide a system guarantee for a clear responsibility, innovation-driven, and healthy competition in drug regulation, stimulating industry vitality and promoting high-quality development in the pharmaceutical sector [1][2]. - The regulations support the development of new industry formats, allowing for segmented production of drugs to meet urgent clinical needs and public health emergencies, thereby enhancing production capacity and ensuring drug availability [2]. - The regulations optimize the listing process for innovative drugs, allowing commercial-scale batches to be sold after obtaining approval documents, which accelerates the availability of innovative treatments to patients and reduces operational costs for companies [3]. Group 2: Quality Management and Safety Assurance - The regulations establish a comprehensive regulatory system for prescription drugs, ensuring safe medication practices by holding medical institutions and pharmaceutical companies accountable for prescription management [6]. - The regulations standardize online drug sales, requiring third-party platforms to establish quality management systems and clarify responsibilities, thus balancing convenience and safety in drug distribution [7]. - The regulations enhance the management of drug use in medical institutions, mandating strict protocols for drug procurement, storage, and reporting of adverse reactions to safeguard patient health [7]. Group 3: Development of Traditional Chinese Medicine - The regulations promote the standardized cultivation and breeding of traditional Chinese medicinal materials, addressing quality stability issues and supporting the sustainable development of the industry [4]. - The regulations encourage the implementation of quality management standards for traditional Chinese medicinal materials, providing legal support for their comprehensive development [4]. Group 4: Overall Impact - The revision of the regulations is expected to drive structural optimization and upgrading in the pharmaceutical industry, ensuring high-level safety and significantly impacting the health-first development strategy and the promotion of high-quality growth in the pharmaceutical sector [8].